To the Editor: Brukner’s personal perspective in a recent issue of the Journal highlights the inherent difficulty of managing patients taking warfarin.1 Although Brukner advocates life-long warfarin therapy for patients who have experienced a pulmonary embolism, we believe few clinicians would be willing to expose their patients to the increased risk of haemorrhage associated with long-term warfarin therapy, especially if a transient risk factor for venous thromboembolism (VTE) existed (such as frequent air travel, in Brukner’s case).
The full article is accessible to AMA
members and paid subscribers.
Login to MJA or subscribe now.
- Monash University, Melbourne, VIC.
Correspondence: amit_verma5@hotmail.com
- 1. Brukner PD. Stop taking warfarin? No way! Med J Aust 2009; 190: 704. <MJA full text>
- 2. Martin JH. Pharmacogenetics of warfarin — is testing clinically indicated? Aust Prescr 2009; 32: 76-80.
- 3. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000; 96: 1816-1819.
- 4. Bodin L, Verstuyft C, Tregouet DA, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005; 106: 135-140.
- 5. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106: 2329-2333.
Online responses are no longer available. Please refer to our instructions for authors page for more information.